FLAG方案治疗难治及复发性急性髓性白血病的效果  

FLUDARABINE,CYTARABINE AND G-CSF REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID LEUKAEMIA

作　　者：王朝晖[1] 韩波[1] 范传波[1] 王九河[1] 洪青[1] 刘俊玲[1] 乌庆超[1] 

机构地区：[1]青岛市海慈医院血液科,山东青岛266033

出　　处：《齐鲁医学杂志》2010年第6期485-486,共2页Medical Journal of Qilu

摘　　要：目的观察氟达拉宾+阿糖胞苷+粒细胞集落刺激因子方案(FLAG方案)治疗难治及复发性急性髓性白血病的效果。方法采用FLAG方案治疗难治及复发性急性髓性白血病20例。结果完全缓解8例(40%),部分缓解4例(20%),未缓解5例,死亡3例,有效率60%。主要副作用为胃肠道反应和骨髓抑制。结论 FLAG方案治疗难治及复发性急性髓性白血病效果较好。Objective To evaluate combo therapy with fludarabine, cytarabine, and G-CSF （FLAG） for relapsed and refractory acute myeloid leukaemia （AML）. Methods The combo therapy of FLAG was applied in the treatment of 20 patients with relapsed and refractory AML. Results Eight （40%） patients achieved complete remission （CR）, and four （20%） partial remission, non-remission five, and death three, the effective power being 60%. The main side effects were gastrointestinal tract reactions and bone marrow depression. Conclusion FLAG therapy is effective for relapsed and refractory acute myeloid leukae- mia.

关 键 词：白血病 粒细胞 急性 氟达拉宾 阿糖胞苷 粒细胞集落刺激因子 治疗结果 

分 类 号：R733.712[医药卫生—肿瘤]